Report Overview:
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secretes TSH. Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.
This report provides a deep insight into the global Lanreotide Injection market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Lanreotide Injection market size was estimated at USD 468 million in 2024 and is projected to reach USD 671.90 million by 2032, exhibiting a CAGR of 4.10% during the forecast period.
By Types:
• Sustained Release Formulation
• Long-acting Formula
By Applications: Hospital
Clinic
Key players include:
• Ipsen
• Cipla
• Including or Excluding key companies relevant to your analysis.
